CDIO, CDIOW · CIK 0001870144 · operating
Based in Chicago, Illinois, Cardio Diagnostics Holdings develops epigenetics-based clinical blood tests for cardiovascular disease assessment and risk stratification. The company's primary offerings include Epi+Gen CHD, which provides three-year symptomatic coronary heart disease risk assessment, and PrecisionCHD, an integrated epigenetic-genetic test for coronary heart disease detection. The company also operates Actionable Clinical Intelligence, a platform delivering epigenetic and genetic insights to clinicians for chronic care management in cardiovascular patients.
The company serves multiple customer segments including telemedicine providers, provider organizations such as concierge practices and longevity clinics, and employer organizations. Additional offerings include CardioInnovate360, a research-use-only platform supporting biopharmaceutical discovery and validation for cardiovascular disease applications, and HeartRisk, a software-as-a-service cardiovascular disease risk intelligence platform targeting healthcare providers and organizations.
Cardio Diagnostics operates as a small-scale biotech firm with 13 full-time employees and maintains a Delaware incorporation. The company is publicly traded on Nasdaq. Founded in 2017, the organization focuses on epigenetics-based diagnostic testing within the broader in vitro diagnostics market.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.31 | $-0.31 | +53.0% | |
| 2023 | $-0.66 | $-0.66 | +56.3% | |
| 2022 | $-1.51 | $-1.51 | — | |
| 2021 | — | — | — |